Primary tumor location in stage III colon cancer has prognostic impact on subsequent liver metastasis

Liao, Chun-Kai; Chiang, Jy-Ming; Tsai, Wen Sy; You, Jeng-Fu; Hsieh, Pao Shiu; Hung, Hsin Yuan; Chen, Hong‐Hwa; Tang, Reiping; Chen, Jinn Shiun; Yeh, Chih‐Hua

doi:10.1002/jso.25270

Cited by 11 publications

(11 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Study population in these studies ranged from 24 to 3125 patients. Studies comprised two cohort prospective studies[ 15 , 16 ] (evidence level 2+) and 39 retrospective studies (evidence level 2+ - 2++)[ 8 - 12 , 17 - 50 ], this included 6 papers with pooled analysis (evidence level 2+-2++)[ 10 , 12 , 15 , 16 , 18 , 49 ]. There were no randomised controlled trials.…”

Section: Resultsmentioning

confidence: 99%

“…In 2017 Heise et al[ 22 ] reported a DFS benefit in patients with l -CRCLM undergoing repeat hepatectomy after recurrence of colorectal cancer (HR: 0.19, P = 0.001). Liao et al[ 10 ] studied 1442 patients with stage III CRC who went on to develop CRCLM, and found that patients with left-sided colon cancer had better 3-year DFS (70.9% vs 66.5%, P = 0.033) compared to those with r -CRCLM.…”

Section: Resultsmentioning

confidence: 99%

“…Specifically, 21 of the 38 studies that provided data on OS reported statistically significant inferior OS in patients with r -CRCLM. Liao et al[ 10 ] for example demonstrated in their large study of 1442 patients that patients with l- CRCLM had better 5-year OS, 5-year cancer-specific survival, and 5-year RFS, all with statistical significance. In 2018 Yamashita et al[ 26 ] similarly concluded in their cohort of 725 patients undergoing upfront hepatic resection, that there was a significant survival benefit to having l- CRCLM, but that this benefit was no longer evident after neoadjuvant chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…It has also been suggested by a number of authors that primary tumour location (PTL) - right side versus left side, can influence patterns of hepatic metastatic dissemination and survival[ 6 , 7 ]. For example, a number of studies have demonstrated inferior oncological outcome in patients undergoing surgical resection of CRCLM with right-sided versus left-sided colonic primary tumours[ 8 - 10 ]. This has not been a consistent observation, and others have shown no clear association[ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Impact of primary tumour location on colorectal liver metastases: A systematic review

Bingham¹,

Shetye²,

Suresh³

et al. 2020

WJCO

View full text Add to dashboard Cite

BACKGROUND Colorectal cancer (CRC) is the third most common cause of cancer-related death worldwide. Despite significant advances in screening, surgical management and adjuvant therapies, average 5-year survival seldom exceeds 60% in most developed nations. Metastatic disease represents the primary cause of mortality in patients with CRC, and the liver is the most common location for distant tumour spread. Up to 25% of patients are found to have synchronous liver metastases at the time of diagnosis and a further 30%-40% will develop metachronous disease in the course of follow-up. It has been suggested that primary tumour location [right side versus left side, primary tumour location (PTL)] can influence oncological outcomes in this patient group and that this should be considered in prognostic models and therapeutic decision-making algorithms. This suggestion is not universally accepted and there have been conflicting reports in the literature to date. AIM To provide a comprehensive summary of the available evidence regarding the impact of PTL on oncological outcomes in patients with colorectal cancer liver metastases (CRCLM). METHODS MEDLINE, EMBASE and COCHRANE were searched for relevant publications using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses methodology. Data on oncological outcomes was then extracted from full text articles that met the predefined inclusion criteria. RESULTS A total of 41 studies were identified that met predefined inclusion criteria for this review. In 21 out of 38 studies that provided data on overall survival, a statistically significant improvement in overall survival was reported in patients with left sided primary tumours. These studies included a total of 13897 patients compared with 4306 patients in the studies that did not show a significant difference. Eight studies noted a similar trend towards improved disease-free or progression-free survival. Several authors observed distinct patterns of relapse after treatment of hepatic metastases according to PTL; for example hepatic recurrence after treatment of CRCLM appears to occur more aggressively with right-sided CRC. CONCLUSION Taken together, the findings of the present review indicate that PTL may have a role as an independent prognostic factor when determining treatment and disease surveillance strategies in CRC. The mechanisms responsible for this variation remain poorly understood, but are likely to relate to molecular, histological and embryological differences, as well as inherent differences in therapeutic sensitivity.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of primary tumour location on colorectal liver metastases: A systematic review

Bingham¹,

Shetye²,

Suresh³

et al. 2020

WJCO

View full text Add to dashboard Cite

show abstract

“…Adam et al 30 Umeda et al 31 Huang et al 32 Mavros et al 33 Viganò et al 34 Connor et al 35 Eefsen et al 36 Schirripa et al 37 Norén et al 38 Sasaki et al 20 Shindoh et al 39 Amikura et al 40 Creasy et al 22 Dupré et al 41 Liang et al 43 Rhu et al 44 Sultana et al 45 Wang et al 46 Yamashita et al 21 Yamashita et al 21 Goto et al 47 Berardi et al 48 Cremolini et al 49 Engstrand et al 50 Goffredo et al 51 lmai et al 52 Koch et al 53 Laengle et al 54 Ledys et al 55 Liao et al 56 Lionti et al 57 Loosen et al 58 Makowiec et al 59 Margonis et al 60 Marques et al 24 Oshi et al 61 Palkovics et al 62 Shigematsu et al 63 Vallance et al 64 Wang et al 23 Wang et al 65 Zheng et al 66 Prediction interval 0·1 0 ·5 1 2 10…”

Section: Fig 2 Forest Plots Showing Impact Of Primary Tumour Locatiomentioning

confidence: 99%

Meta-analysis of the association between primary tumour location and prognosis after surgical resection of colorectal liver metastases

Wang

Zhang

Wang

et al. 2019

British Journal of Surgery

View full text Add to dashboard Cite

Background Primary tumour location is emerging as an important prognostic factor in localized and metastatic colorectal cancers. However, its prognostic role in colorectal liver metastasis (CRLM) after hepatectomy remains controversial. A systematic review and meta‐analysis was undertaken to evaluate its prognostic value. Methods References were identified through searches of PubMed, Embase, Web of Science and the Cochrane Library comparing overall or disease‐free survival after hepatic resection between patients with CRLM originating from right‐ or left‐sided colorectal cancers. Data were pooled using hazard ratios (HRs) and 95 per cent confidence intervals according to a random‐effects model. Meta‐regression and subgroup analyses were conducted to assess the effect of underlying confounding factors on HR estimates and to adjust for this. Results The final analysis included 21 953 patients from 45 study cohorts. Compared with left‐sided primary tumour location, right‐sided location was associated with worse overall survival (HR 1·39, 95 per cent c.i. 1·28 to 1·51; P < 0·001; prediction interval 1·00 to 1·93), and also tended to have a negative impact on disease‐free survival (HR 1·18, 1·06 to 1·32; P = 0·004; prediction interval 0·79 to 1·75). Subgroup analysis showed that the negative effect of right‐sided primary tumour location on overall survival was more prominent in the non‐Asian population (HR 1·47, 1·33 to 1·62) than the Asian population (HR 1·18, 1·05 to 1·32) (P for interaction <0·01). Conclusion This study demonstrated a prognostic role for primary tumour location in patients with CRLM receiving hepatectomy, especially regarding overall survival. Adding primary tumour location may provide important optimization of prognosis prediction models for CRLM in current use.

show abstract

Prognostic value of the combination of primary tumor location and RAS mutational status on patients with colorectal liver metastasis undergoing hepatectomy

Yan

Wang

Bao

et al. 2022

Journal of Surgical Oncology

View full text Add to dashboard Cite

Objective To assess prognostic influences of RAS mutational status and primary tumor site on cases with colorectal liver metastasis (CRLM) who underwent hepatectomy. Methods Clinicopathological data of 762 patients with CRLM who underwent hepatectomy between January 2000 and November 2018 were retrospectively analyzed. The left‐sided tumors (LST) included tumors located in the splenic flexure, descending colon, sigmoid colon, and rectum; while right‐sided tumors (RST) included those located in the cecum, ascending colon, and transverse colon. RAS mutational status was determined using Sanger sequencing or next‐generation sequencing, including KRAS (Codons 12, 13, and 61) and NRAS (Codons 12, 13, and 61), which were defined as wild‐type (RASwt) and mutant‐type (RASmut), respectively. Survival curves were plotted using the Kaplan–Meier plotter and compared by the log rank test. The clinicopathological data were analyzed using univariate and multivariate analyses. Results The 5‐year overall survival (OS) in the LST group was longer than that in the RST group (OS: 47.1% vs. 31.0%, p = 0.000, respectively), and the OS in the RASwt group was longer compared with that in the RASmut group (OS: 53.6% vs. 24.0%, p = 0.000). Besides, overall survival of the patients after hepatectomy was alternative, which was stratified by primary tumor site, with the 1‐, 3‐, and 5‐year survival rates of 93.1%, 62.1%, and 47.1% for patients with LST, and 91.1%, 42.8%, and 31.0% for patients with RST, respectively. OS and disease‐free survival (DFS) were significantly different stratified by RAS mutational status, with the 1‐, 3‐, and 5‐year rates of 96.9%, 67.9%, and 53.6% for patients with RASwt tumors, and 85.7%, 41.5%, and 24.0% for patients with RASmut tumors, respectively. The 1‐, 3‐, and 5‐year DFS rates were 51.9%, 30.0%, and 26.7% for patients with RASwt tumors, and 35.8%, 18.2%, and 14.9% for patients with RASmut tumors, respectively. The results of multivariate analysis showed that RAS mutational status and primary tumor site were both independent influencing factors of OS. Conclusion RAS mutational status and primary tumor site affect OS independently in CRLM patients undergoing hepatectomy. The worse prognosis of RST cannot be simply attributed to the imbalance of RAS mutational status in different primary tumor sites.

show abstract

Primary tumor location in stage III colon cancer has prognostic impact on subsequent liver metastasis

Cited by 11 publications

References 27 publications

Impact of primary tumour location on colorectal liver metastases: A systematic review

Impact of primary tumour location on colorectal liver metastases: A systematic review

Meta-analysis of the association between primary tumour location and prognosis after surgical resection of colorectal liver metastases

Prognostic value of the combination of primary tumor location and RAS mutational status on patients with colorectal liver metastasis undergoing hepatectomy

Contact Info

Product

Resources

About